

**Supplementary Table 2.** Modified Newcastle-Ottawa Quality Assessment Scale for Included Studies

First author (year)	Selection <sup>a</sup>			Outcome <sup>b</sup>			Total score
	1	2	3	1	2	3	
Pestour (2018) <sup>1</sup>	-	+	+	-	+	+	4
Feagan (2018) <sup>2</sup>	+	+	+	+	+	+	6
Chapuis-Biron (2020) <sup>3</sup>	+	+	+	+	+	+	6
Schwartz (2020) <sup>4</sup>	-	+	+	+	+	+	5

<sup>a</sup>Selection: 1, representativeness of the exposed cohort (adequately describes baseline characteristics, previous/concomitant therapies of patients started on vedolizumab therapy); 2, ascertainment of exposure (adequately describes study definitions of perianal fistulizing disease adequately); 3, outcome of interest not present at start of study.

<sup>b</sup>Outcome assessment: 1, assessment of outcome (adequately describes definition of perianal fistulizing disease healing); 2, adequacy of duration of follow-up; 3, adequacy of completeness of follow-up (all subjects accounted for at end of study).

## REFERENCES

1. Pestour S, Nancey S, Charlois A, et al. Influence of disease location on vedolizumab effectiveness in inflammatory bowel diseases: a real-life multicenter experience. *Hum Health Pathol* dumas-01623835 [Preprint]. 2017 [cited 2021 May 1]. <https://dumas.ccsd.cnrs.fr/dumas-01623835>.
2. Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2. *J Crohns Colitis* 2018;12:621-626.
3. Chapuis-Biron C, Bourrier A, Nachury M, et al. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. *Aliment Pharmacol Ther* 2020;51:719-727.
4. Schwartz D, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. A randomized double-blind phase 4 study to evaluate the safety and proportion of subjects with fistula healing in 2 dose regimens of Entyvio (vedolizumab IV) in the treatment of fistulizing Crohn's disease (ENTERPRISE) [Internet]. c2020 [cited 2020 Jul 1]. <https://clinicaltrials.gov/ct2/show/NCT02630966>.